Alerta

CORONAVIRUS VACCINE

Resumen de: US20260091107A1

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus Infection, preferably a Coronavirus infection.

METHOD FOR PREVENTING INFECTION OF A HEALTHY PERSON OR A HEALTHY ANIMAL WITH A VIRUS THAT USES ACE2 AS A RECEPTOR, BINDING INHIBITOR AND MEDICAL DEVICE

Resumen de: US20260091066A1

A composition containing a culture supernatant of dental pulp-derived stem cells, adipose-derived stem cells, umbilical cord-derived stem cells or immortalized stem cells thereof in which the composition contains angiotensin-converting enzyme 2 (ACE2) and is used for administration to a healthy person or a healthy animal for preventing infection of the healthy person or the healthy animal with a virus that uses ACE2 as a receptor can be used as a medicine for preventing infection with a virus that uses ACE2 as a receptor, such as COVID-19, or the like when administered to a healthy person or a healthy animal.

LAMP ASSAY SYSTEM FOR DETECTION OF RESPIRATORY VIRUS

Resumen de: US20260085367A1

A LAMP assay system for detection of a respiratory virus is disclosed. The LAMP system includes a LAMP reaction mixture having a primer kit, a strand-displacing polymerase and deoxyribonucleoside triphosphates for amplifying a target sequence. The primer kit includes at least one of a first primer set specific to SARS-CoV-2, a second primer set specific to Influenza A, and a third primer set specific to Influenza B. The first primer set includes primers having nucleotide sequences of SEQ ID NOs: 1 to 6 and SEQ ID NOs: 13 to 18. The second primer set includes primers having nucleotide sequences of SEQ ID NOs: 25 to 30. The third primer set includes primers having nucleotide sequences of SEQ ID NOs: 44 to 49.

CHEMICAL COMPOUND COMPRISING A TRIAZINE GROUP AND METHOD FOR PRODUCING SAME

Resumen de: US20260085087A1

A chemical compound having a triazine group and a method for production thereof are related to novel compounds and methods for production thereof in nucleotide chemistry. In particular, the present invention relates to nucleotides and oligonucleotides comprising a modified phosphate group, and to the method for production thereof. The present invention may be used in cytological studies, in DNA- or RNA-containing pathogen diagnostics, in gene therapy as well as in treating various bacterial and viral diseases, including COVID-19. The objective of the present invention is to provide compounds having a therapeutic potential as well as to develop the available method for production thereof.

BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF

Resumen de: US20260085063A1

The present disclosure relates, in part, to SARS-CoV-2 papain-like protease (PLpro) inhibitor compounds of Formula (I), pharmaceutical compositions thereof, and methods of using the same for promoting an antiviral effect in a subject and/or treating, preventing, and/or ameliorating a viral infection in a subject:

SYSTEMS AND METHODS FOR TREATING BLOOD CLOTS WITH NERVE STIMULATION

Resumen de: US20260088185A1

Systems and methods are provided for treating blood clots associated with a replicating pathogen, such as a virus in the coronaviridae family. The systems and methods include applying an electrical impulse transcutaneously through the outer skin surface of the patient to a cervical branch of the vagus nerve of the patient. The electrical impulse is sufficient to reduce a number of antibodies associated with blood clotting to reduce a level of blood clotting in the patient. The systems and methods are particularly useful for treating post-COVID conditions or post-acute sequelae of COVID-19 that develop in “long-haul” or COVID patients.

SIALIC ACID COMPOSITIONS FOR THE USE OF INHIBITING AND TREATING CORONAVIRUS INFECTION

Resumen de: US20260083762A1

The present invention relates to the use of compositions comprising sialic acid to inhibit or treat coronavirus infections, and in particular those caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).

METHOD AND REAGENTS FOR ULTRASENSITIVE IMMUNOASSAY

Resumen de: WO2026064422A1

Disclosed are assays, reagents, and methods for ultrasensitive detection of target molecules. The assay comprises fusion proteins including binding moieties, such as antibodies, nanobodies (VHH/VNAR), or aptamers, linked to nonfunctional fragments of a protein. In the presence of a target molecule, the binding moieties recognize distinct target regions and bring the protein fragments into close proximity, reconstituting a functional protein that generates a detectable signal. Linkers connecting the fusion components may be flexible peptides or polypeptides that spontaneously form dimers, trimers, or tetramers, thereby providing multivalent fusion proteins with enhanced sensitivity. The reconstituted protein may produce luminescent, fluorescent, colorimetric, or spectroscopic signals detectable by microplate readers, handheld luminometers, or lateral flow devices. The invention encompasses solid-phase, homogeneous, and lateral flow assay formats for detecting viruses, bacteria, proteins, peptides, or small molecules, including GLRaV-3, SARS-CoV-2, PSA, and E. coli. The disclosed assays exhibit improved specificity, reduced background, and enhanced signal-to-noise ratios

PANCORONAVIRUS BIOMARKER PANEL

Resumen de: WO2026064358A1

The present disclosure provides pancoronavirus biomarker panels that can be used to detect a wide variety of characterized coronavirus strains and, in some embodiments, emerging or novel coronavirus strains. In certain embodiments, this detection can be carried out in a single, highly multiplexed nucleic acid amplification assay.

MEASUREMENT OF LUNG FUNCTIONS BY PULMONARY GAS EXCHANGE

Resumen de: US20260083351A1

Provided are methods and systems for measuring lung function, such as shunt and deadspace, using pulmonary gas exchange in management and treatment of pulmonary diseases including COVID-19.

MODULAR BACTERIOPHAGE T4 NANOPARTICLE PLATFORM ENABLES RAPID DESIGN OF DUAL COVID-19-FLU MUCOSAL VACCINES

Resumen de: US20260083835A1

A non-infections bacteriophage T4 nanoparticle vaccine composition includes a bacteriophage capsid and at least one antigen displayed on the surface of the capsid or packaged in its interior. The vaccine is administered intranasally and is free of an adjuvant. The antigen is selected from respiratory viruses including coronavirus and influenza.

METHODS FOR TREATING SARS COV-2 INFECTIONS

Resumen de: EP4714452A1

Provided are methods for treating 2019-nCoV virus (SARS-CoV-2) infections by administering nucleosides and prodrugs thereof, of Formula I:wherein the l' position of the nucleoside sugar is substituted.

METHODS OF TREATING RESPIRATORY DISEASE WITH DEUPIRFENIDONE

Resumen de: EP4714943A2

Disclosed herein is a method of treating a viral, e.g., SARS-CoV-2, respiratory disease or infection, such as COVID-19 related pneumonia, that includes administering deuterium-enriched pirfenidone, e.g., daily for 3 months or more, such that the viral respiratory disease or infection is treated. The treating is effective in preventing the development of, halting the progression of, or slowing the progression of one or more of pulmonary fibrosis, respiratory complications of the viral respiratory disease or infection, respiratory symptoms of the viral respiratory disease or infection or pulmonary dysfunction.

A RECOMBINANT SARS-COV-2 S GLYCOPROTEIN TRIMER, PROTEOLIPOSOMES COMPRISING SUCH A TRIMER AND THEIR USE AS A VACCINE

Resumen de: WO2026057765A1

The present invention concerns a recombinant SARS-CoV-2 S glycoprotein trimer stabilized in a conformation that is anterior to the post-fusion conformation, as well as a proteoliposome comprising such a recombinant trimer and a vaccine based on such a proteoliposome. The invention also relates to a method of treating or preventing a SARS-CoV-2 infection in a subject using such a vaccine.

IMMUNIZATION METHOD AGAINST INFECTION BY SARS-CoV-2

Resumen de: US20260077035A1

A pDNA-based vaccine against SARS-CoV-2 and methods for preventing or treating COVID-19 using it.

COMPOSITION FOR THE TREATMENT OF COVID-19

Resumen de: US20260076979A1

A composition for the treatment of COVID-19 is disclosed, including a first composition including approximately 10 mg of dexamethasone. The first composition is combined with a second composition including between approximately 48 mg to approximately 80 mg of triamcinolone acetonide, sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80.

PROTAC DEGRADERS OF SARS-COV-2 MAIN PROTEASE

Resumen de: US20260077050A1

The present disclosure relates to certain molecules, pharmaceutical compositions containing them, and methods of using them to treat viral infections.

Methods For Reducing Or Preventing SARS-COV-2 Infection And Transmission

Resumen de: US20260077052A1

The application provides a method to prevent or reduce the transmission of a coronavirus, such as a SARS-COV-2 variant, or a paramyxovirus from an infected subject to other uninfected subjects, comprising administrating an anti-viral peptide conjugate to the infected subject, the uninfected subject, or both.

TRACHEAL INTRODUCER SHEATH AND SIMPLIFIED TRACHEAL INTRODUCER SHEATH

Resumen de: US20260077146A1

According to the CDC, the same month (March, 2020) they declared COVD-19 a pandemic, nearly 25% of confirmed COVID-19 hospitalized patients required intubation, or ventilator use. More recently, in the US, during the summer of 2021, child intubations more than quadrupled, when the Delta variant predominated.As Omicron and additional COVID-19 variants continue to arise globally, there will be an increasing number of sudden spikes in critical illness and respiratory failure. Preparedness with efficacious airway tools that optimize success rate of intubations is critical.Without the proper tools, intubation procedures take excessive time, and can fail entirely, causing diminished central nervous system oxygenation and potentially permanent neurologic sequelae. Airway adjuncts such as the Tracheal Introducer Sheath (TIS) and Simplified Tracheal Introducer Sheath (STIS) hold immense potential to improve chances of successful intubations.The TIS is a STIS with an added articulating mechanism, but otherwise is a similar device. For the purposes of further explanation, the TIS refers to both TIS and STIS unless otherwise specified.TIS is an adjunct medical device for control and guidance of any form of tracheal introducer device through the glottic opening of a patient's airway. This facilitates endotracheal intubation by passage of the endotracheal tube.An airway introducer is placed within and controlled by the TIS, a mechanically specialized sheath, open at both ends, and covering

Pan-Neutralizing SARS-CoV-2 mAb Composition and Methods of Treatment Thereof

Resumen de: US20260078170A1

Among the various aspects of the present disclosure is the provision of compositions and methods of use of mAb that prevent, inhibit, or reduce the transmissivity of SARS-CoV-2 infections.

Compounds and methods for treating diseases caused by SARS-CoV-2 and other coronaviruses

Resumen de: US20260076973A1

Provided are compounds and methods of treating diseases caused by a Coronaviridae virus such as SARS-CoV-2, SARS-CoV, and MERS-CoV coronaviruses by administering nitrogen-containing heterocyclic compounds. SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome), and, particularly, COVID-19 are highly contagious diseases with high mortality rate responsible for tens of millions of infections and almost two million deaths around the globe.

COMPOSITION FOR THE TREATMENT OF COVID-19

Resumen de: US20260076980A1

A composition and method for treating COVID-19 includes a first component including approximately 10 mg of dexamethasone and a second component including approximately 48 mg to 80 mg of triamcinolone acetonide in combination with sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80. When combined, the formulation provides dual-steroid therapy that reduces the need for tapering associated with high-dose dexamethasone, thereby minimizing adverse effects such as immunosuppression and secondary pneumonia. The composition is administered via injection and is effective for alleviating symptoms in patients with mild, moderate, or severe COVID-19 infections.

METHOD AND REAGENTS FOR ULTRASENSITIVE IMMUNOASSAY

Resumen de: US20260079158A1

Disclosed are assays, reagents, and methods for ultrasensitive detection of target molecules. The assay comprises fusion proteins including binding moieties, such as antibodies, nanobodies (VHH/VNAR), or aptamers, linked to nonfunctional fragments of a protein. In the presence of a target molecule, the binding moieties recognize distinct target regions and bring the protein fragments into close proximity, reconstituting a functional protein that generates a detectable signal. Linkers connecting the fusion components may be flexible peptides or polypeptides that spontaneously form dimers, trimers, or tetramers, thereby providing multivalent fusion proteins with enhanced sensitivity. The reconstituted protein may produce luminescent, fluorescent, colorimetric, or spectroscopic signals detectable by microplate readers, handheld luminometers, or lateral flow devices. The invention encompasses solid-phase, homogeneous, and lateral flow assay formats for detecting viruses, bacteria, proteins, peptides, or small molecules, including GLRaV-3, SARS-CoV-2, PSA, and E. coli. The disclosed assays exhibit improved specificity, reduced background, and enhanced signal-to-noise ratios.

SARS-COV2 ANTIBODIES AND USES THEREOF

Resumen de: US20260078171A1

The present disclosure is directed to antibodies and antigen binding fragments thereof, or combinations of antibodies and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. The disclosure contemplates conjugates of anti-CoV-S antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the disclosure contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.

TOUCHLESS COMPUTER INTERFACES

Resumen de: US20260080738A1

This application is directed to touchless interfaces. Some embodiments disclosed are directed to plug and play replacements for casino gaming machine touch-based interfaces on, e.g., slot machines. Existing slot machine interfaces can be replaced with touchless interfaces of the inventive subject matter to enable touchless interaction with gaming machines. This allows people in casinos to minimize contact with gaming machines to stymy the spread of diseases like COVID-19.

PREPARATION METHOD AND APPLICATION OF RECOMBINANT PROTEIN OF NOVEL CORONAVIRUS OR RECOMBINANT PROTEIN OF HUMAN ANGIOTENSIN CONVERTING ENZYME-2

Resumen de: NL2038573B1

The present invention relates to the technical field of genetic engineering of molecular biology and medical science, and specifically discloses a preparation method and application of recombinant protein of novel coronavirus or recombinant protein of human angiotensin converting enzyme—2. According to the present invention, the two recombinant proteins are prepared in Escherichia coli of a prokaryotic system by using genetic engineering technology, which can be successfully and efficiently expressed, have good antigenicity, and can be well configured to detect a neutralizing antibody of the novel coronavirus. Compared with other traditional methods, the present invention is safer and more efficient, and has positive significance for basic research and clinical detection in the novel coronavirus.

A RECOMBINANT SARS-COV-2 S GLYCOPROTEIN TRIMER, PROTEOLIPOSOMES COMPRISING SUCH A TRIMER AND THEIR USE AS A VACCINE

Resumen de: EP4710948A1

The present invention concerns a recombinant SARS-CoV-2 S glycoprotein trimer stabilized in a conformation that is anterior to the post-fusion conformation, as well as a proteoliposome comprising such a recombinant trimer and a vaccine based on such a proteoliposome. The invention also relates to a method of treating or preventing a SARS-CoV-2 infection in a subject using such a vaccine.

COMBINATION VACCINE FOR PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS

Resumen de: EP4710936A1

Disclosed is a combination vaccine for prevention of influenza and novel coronavirus infections. The combination vaccine for vaccination against influenza and novel corona viruses was obtained by inactivating all influenza virus particles and all novel coronavirus particles respectively, thereby inducing the antibodies to each virus without affecting each vaccine effect, so that the defensive effects were obtained against the attacks of each virus. In addition, the combination vaccine with this combination exhibited favorable neutralizing antibody induction and defensive effects to the attacks of these viruses even without addition of an adjuvant.

SELF-REPLICATING RNA AND USES THEREOF

Resumen de: EP4711458A2

The present disclosure relates to self-replicating RNA encoding an antigen from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof.

HIGH-AFFINITY PROTEIN BINDERS AND USES THEREOF

Resumen de: WO2026055147A1

Provided herein are proteins that include a Vascular Endothelial Growth Factor A (VEGF-A) protein binding domain; proteins that include an Epstein-Barr Virus BCL-2 homolog (BHRF1) protein binding domain; proteins that include a Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) RBD protein binding domain; proteins that include an Interleukin-7 receptor subunit alpha (IL7R-α) protein binding domain; proteins that include a Programmed death-ligand 1 (PD-L1) protein binding domain; proteins that include a Tropomyosin-receptor kinase A (Trk-A) protein binding domain; and proteins that include an Interleukin-17 (IL-17A) protein binding domain.

IMMUNOGENIC COMPOSITIONS AND VACCINES IN THE TREATMENT AND PREVENTION OF INFECTIONS

Resumen de: AU2026201333A1

The invention is directed to portions of proteins of gram-positive bacteria, gram-negative, acid-fast bacteria (Mycobacteria, Staphylococcus) and/or virus (SARS-COV-2, Influenza), and antibodies reactive against these portions that can be formulated as immunogenic compositions and vaccines for the treatment and prevention of a microbial and/or viral infections. Preferably, compositions of the invention contain one or more portions of selected microbial and/or viral proteins that, upon administration to a subject, generate an effective cellular and/or humoral immune response, modulate immunity and a cytokine response. Effective responses involve an increased generation of antibodies that enhance immunity against an infection and promote an enhanced a phagocytic response. Monoclonal antibodies produced against these peptides enhance phagocytosis and killing of bacteria, viruses, and other microbes by phagocytic cells, and enhance clearance from the blood. and enhance clearance from the blood. eb e b a n d e n h a n c e c l e a r a n c e f r o m t h e b l o o d

COMPUTERIZED DECISION TOOL FOR SARS-COV-2 VARIANTS PREDICTION

Resumen de: US20260074014A1

Technology is disclosed for a method for screening genetic mutations that can be used to predict vaccine composition, the method may include selecting a plurality of genome samples, partitioning the plurality of genome samples into N groups, where N is an integer larger than 1, identifying genomic isolates with phenotypic statuses from each of the N groups of genome samples by training at least one linear support vector machine with the genome samples, the identification of the isolates between each of the N groups of the genomic isolates performed in parallel, and assessing the identified genomic isolates using a performance metric.

SARS CORONAVIRUS 2 RECOMBINANT VECTORS EXPRESSING REPORTER GENES, DERIVED FROM GH CLADE SARS CORONAVIRUS 2 OF KOREAN ISOLATE, AND THE PRODUCTION METHOD THEREFOR

Resumen de: US20260071190A1

There are SARS coronavirus 2 recombinant vectors derived from a GH clade SARS coronavirus 2 Korean isolate, which express distinct reporter genes, and the production method thereof. A full-length clone of a SARS coronavirus 2 Korean isolate or a derivative thereof, according to one embodiment, can be used as a standard material for evaluating the efficacy of therapeutic agents and vaccines in cell lines and animal models while maintaining infectivity and replication capacity when restored to viruses, can be used to develop a large-scale testing method for therapeutic agent development, and can be used to develop attenuated vaccine strains. In addition, a SARS coronavirus 2 recombinant vector derived from a Korean isolate or a derivative thereof, expressing a reporter gene, can be used for high-capacity, rapid drug screening in the development of antibody therapeutic agents and antiviral agents.

METHODS FOR EXPANDING SARS-COV2-ANTIGEN-SPECIFIC T CELLS, COMPOSITIONS AND USES RELATED THERETO

Resumen de: US20260071235A1

Provided herein are methods for preparing and characterizing SARS-cov2 antigen specific immune cell cultures and preparations and methods of using the same in adoptive immunotherapy for cancer, infections, and immune disorders. Also provided are compositions and methods for generating immune calls expressing synthetic antigen binding receptors targeting SARS-cov2 and methods of use of these cells for the treatment and prevention of COVID-19. Also provided are compositions and methods for determining immune response to SARS-cov2 in a subject, detecting SARS-cov2, measuring cytotoxicity induced by SARS-cov2, and detecting the expression and cytotoxicity of synthetic antigen binding receptors targeting SARS-cov2.

NUCLEIC ACID VACCINES ENCAPSULATED WITH NANOALUMINOSILICATE AGAINST MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-CoV)

Resumen de: US20260069675A1

A MERS-CoV vaccine with nucleic acid sequences having at least 90% identity to the spike gene of a MERS-CoV strain as a preventive measure against MERS-CoV infections is described. The nucleic acid sequences may include plasmid DNA (pDNA) or messenger RNA (mRNA) that are encapsulated by aluminosilicates. The aluminosilicates may be functionalized with aminopropyltrimethoxysilanes.

ANTI-SARS-COV-2-SPIKE GLYCOPROTEIN ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS

Resumen de: US20260069689A1

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

MITOCHONDRIA-FACILITATED DELIVERY OF MRNA

Resumen de: WO2026055709A1

Among the various aspects of the present disclosure is the provision of compositions and methods of a gene delivery system. The compositions include at least one therapeutic molecule and an isolated mitochondria, and optionally further complexed to a lipid nanoparticle. Methods of molecule delivery include the use of isolated mitochondria as a vector for the delivery of the therapeutic molecule. A method of treating a patient in need of a gene vaccine is also described, in which the mRNA of the administered composition encodes a vaccine antigen, including but not limited to at least a portion of a SARS-CoV-2 spike protein.

Use of N-Chlorotaurine for Treatment and Prevention of Viral Infections

Resumen de: US20260069556A1

Methods for treatment and prevention of a viral infection in an animal, including a respiratory infection, like a coronavirus such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Influenza A such as H1N1, H3N2, H5N1, or respiratory syncytial virus. The compositions and methods include a therapeutically effective amount of about a 1% solution of N-chlorotaurine in water. The methods include administering N-chlorotaurine by eye drop to the eyes, nasal spray to the nostrils, by oral spray to the throat, by nebulizer to the lungs, and by cannula to the mammary glands.

SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUND AS PHARMACEUTICAL FOR TREATMENT OR PREVENTION OF COVID-19

Resumen de: EP4707279A1

The present invention provides a compound useful for the treatment or prevention of SARS-CoV-2 novel coronavirus infection.The present invention relates to a compound represented by formula (I), its enantiomer, or a pharmaceutically acceptable salt thereof:whereinring A, R1 and R7, R2 and R4, X and Y, as well as Z are according to the definitions as described in the specification;use thereof for the treatment or prevention of SARS-CoV-2 novel coronavirus infection; and pharmaceutical compositions comprising the same.

SARS-COV-2 VACCINE COMPOSITIONS

Resumen de: AU2024263334A1

Disclosed herein are coronavirus (CoV) Spike (S) polypeptides, including naturally and non-naturally occurring polypeptides, and nanoparticles and immunogenic compositions comprising the same, which are useful for stimulating immune responses against various SARS-CoV-2 strains. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

Immuno-therapeutic chemical compositions and uses thereof

Resumen de: US12569492B1

Disclosed herein are methods for the treatment of cancer and inflammatory-based diseases and disorders, such as coronavirus colds and as a therapy against COVID-19. ImmunoFolate has been shown to reduce the incidents of colds and flus. In one embodiment is a method of treating cancer comprising administration of ImmunoFolate. In another embodiment is a method of treatment inflammatory-based disease and disorders comprising administration of ImmunoFolate.

Combination Vaccine For Prevention Of Influenza And Coronavirus Infections

Resumen de: US20260061046A1

Disclosed is a combination vaccine for prevention of influenza and novel coronavirus infections. The combination vaccine for vaccination against influenza and novel corona viruses was obtained by inactivating all influenza virus particles and all novel coronavirus particles respectively, thereby inducing the antibodies to each virus without affecting each vaccine effect, so that the defensive effects were obtained against the attacks of each virus. In addition, the combination vaccine with this combination exhibited favorable neutralizing antibody induction and defensive effects to the attacks of these viruses even without addition of an adjuvant.

SARS-COV-2 VACCINES AND THERAPEUTICS

Resumen de: WO2026047716A1

The present disclosure relates generally to receptor binding domain of SARS-CoV- 2 and nucleic acids encoding the receptor binding domain, wherein the receptor binding domain comprises one or more mutations at amino acid positions selected from the group comprising R28T, K38V or T, K126T, F138L, A157V, V165del, E166A or K or P, Q175E, S176P, A202G, or a combination thereof compared to SEQ ID NO: 1. Such a receptor binding domain can be included as one of the components or constituents of polypeptide or multisubunit peptide disclosed herein, including the nucleic acids encoding them.

SARS-COV-2 IMMUNOGENIC COMPOSITIONS

Resumen de: WO2026047603A1

Disclosed herein are compositions comprising protein antigens and RNA encoding the same (eg., compositions comprising protein antigens and RNA encoding antigens) that can be used to induce an immune response against SARS-CoV-2. Also disclosed herein are immunogenic compositions and medical preparations comprising the same, and methods of making and using the same. In some embodiments, the technologies provided herein can be used to address and/or overcome immune imprinting in SARS-CoV-2.

MACHINE-LEARNING-BASED METHOD FOR SCREENING CROSS-DIFFERENTIALLY EXPRESSED GENES BETWEEN LUNG CANCER AND COVID-19 INFECTION AND CORRESPONDINGLY SCREENING PROGNOSTIC GENES OF LUNG CANCER

Resumen de: WO2026040166A1

The present invention belongs to the technical field of bioinformatics, and relates to a machine-learning-based method for screening cross-differentially expressed genes between lung cancer and COVID-19 infection and correspondingly screening prognostic genes of lung cancer. The method comprises: acquiring cross-differentially expressed genes between lung cancer and COVID-19; screening the cross-differentially expressed genes between lung cancer and COVID-19 infection; using Cox regression and LASSO regression to correspondingly screen prognostic genes of lung cancer; and using a K-M survival analysis method, GO and KEGG enrichment analysis methods and a protein-protein interaction analysis method to analyze screened-out prognostic genes of lung cancer. The method provided herein can process data, and can also identify intricate patterns in the data, and has relatively high sensitivity and specificity, thereby improving the efficiency and accuracy of screening. The technique can be extended to the research of other diseases, and features universality.

COMPOSITIONS CONTAINING VERTEPORFIN, RIBAVIRIN, GEMCITABINE, OR COMBINATIONS THEREOF AND METHODS OF USE FOR TREATING COVID-19, CANCER, OR NON CANCER DISEASES

Resumen de: US20260053779A1

Disclosed are pharmaceutical formulations and methods using Verteporfin, Ribavirin, and/or Gemcitabine for use in the treatment of diseases by various routes of administration including inhalation, intratumoral, topical and/or systemic injection administration. This invention relates more specifically to the use of Verteporfin, Ribavirin, Gemcitabine, and/or combinations thereof as an inhaled dry powder treatment for COVID-19 and/or other lung infections, cancer and other non-cancer applications, which may be followed by other treatment regimens including radiation therapy, photodynamic therapy, and/or sonodynamic therapy. These pharmaceutical compositions containing one or more of Verteporfin, Ribavirin, and Gemcitabine may be included in pharmaceutical kits containing the compositions, and to methods for the treatment of cancer and non-cancer diseases with the active agents of the pharmaceutical compositions. The administering of Verteporfin alone or in combination with Ribavirin and Gemcitabine may be followed or co-administered with photodynamic and/or sonodynamic therapy (PDT/SDT).

HYDROGEL COMPRISING GLYCEROL AND A CARBOMER FOR TREATING THE RESPIRATORY SYMPTOMS OF COVID-19 DISEASE VIA THE NASAL ROUTE

Resumen de: US20260053741A1

The invention relates to a product for treating viral diseases, such as COVID-19, via the nasal route. The product comprises a hydrogel based on water, glycerol and a carbomer.

METHODS OF PROPHYLAXIS OF CORONAVIRUS INFECTION AND TREATMENT OF CORONAVIRUSES

Resumen de: US20260053745A1

Methods for prophylaxis, treatment, and reduction of infection, re-infection, and transmission rates of Coronaviruses and more particularly Coronavirus Disease 2019 (COVID-19) resulting from a SARS-CoV-2 viral infection with the use of a pharmaceutical preparation comprising one or more coated or uncoated digestive enzymes, such as pancreatic enzymes and porcine pancreatic enzymes are described herein.

HALOPHTHALIMIDE COMPOUNDS AND METHODS OF USE AGAINST TBI, INFLAMMATORY DISORDER, AUTOIMMUNE DISORDER, NEURODEGENERATIVE DISEASE OR VIRAL INFECTION

Resumen de: US20260055061A1

Halophthalimides are disclosed. The halophthalimides may inhibit TNF-α activity, TNF-α synthesis, inflammation, inducible nitric oxide synthase, SARS-CoV-2 virus, or any combination thereof. The halophthalimides may be administered to a subject with a traumatic brain injury, an inflammatory disorder, an autoimmune disorder, a neurodegenerative disease, a viral infection, or any combination thereof. The disclosed halophthalimides have a structure according to Formula I, or a stereoisomer or pharmaceutically acceptable salt, solvate, or hydrate thereof,where R5 isAt least one of R2-R4 or Re is halo.

T CELL BROAD BETACORONAVIRUS VACCINE

Resumen de: AU2024333842A1

The present invention relates to polypeptides, polynucleotides, compositions, microorganisms, vectors and vaccine compositions optimised for the treatment or prophylaxis of a disease or infection caused by Betacoronaviruses, including but not limited to: Embecovirus, Hibecovirus, Merbecovirus, Nobecovirus, Sarbecovirus, MERS-CoV, SARS-CoV-1 and SARS-CoV-2. In particular, the invention provides a vaccine composition comprising a polypeptide, wherein the polypeptide comprises one or more epitope sequences, wherein the one or more epitope sequences have the amino acid sequences of any one or more of the sequences of Table 1, or a variant thereof having at least 70% sequence identity thereto, and wherein the polypeptide sequence is no more than 1400 amino acids in length.

COMPOUNDS WITH ACTIVITY AGAINST SARS-COV-2

Resumen de: WO2024218171A1

Compounds of Formula (I), pharmaceutical compositions containing them and their use in the treatment of a SARS-CoV-2 infection.

ENHANCING THE SOLUBILITY OF SARS-COV-2 INHIBITORS TO INCREASE CLINICAL POTENTIAL

Resumen de: WO2026039749A1

Described herein are soluble HRC-based Hpopeptide inhibitors of coronaviruses identified using structure-guided design to incorporate charged or polar residues at specific sites in the peptide to enhance aqueous solubility. Also described are methods of treating a coronavirus infection using soluble HRC-based hpopeptide inhibitors.

ANTIBODIES AGAINST COVID-19 AND OTHER HUMAN CORONAVIRUSES

Resumen de: AU2024298416A1

The present invention relates to monoclonal antibodies or antigen-binding portion thereof that have a potent neutralizing activity against Coronavirus, in particular against at least one virus selected from SARS-CoV-2, SARS-CoV-1 and variants thereof. The invention relates also to the use of such monoclonal antibodies or antigen-binding portion thereof in therapy, prophylaxis, and diagnosis of Coronavirus, in particular SARS-CoV-2 and/or SARS-CoV-1 dependent diseases.

SARS-COV-2 INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS

Resumen de: US20260049062A1

Provided herein are compounds, pharmaceutical compositions, and methods for treating a SARS-CoV-2 infection.

VALACYCLOVIR AND CELECOXIB FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND COVID-19

Resumen de: US20260048058A1

The present disclosure relates to methods of treating Alzheimer's disease, diseases and/or conditions associated with Covid-19 infection, including long COVID, a post-acute infection syndrome, or symptoms of orthostatic intolerance comprising administration of a therapeutically-effective combination of a COX-2 inhibitor and an antiviral compound.

SPECIFIC REACTION MIXTURE FOR USE IN THE DIAGNOSIS OF COVID-19 WITH ISOTHERMAL AMPLIFICATION METHOD

Resumen de: US20260049367A1

The present invention relates to a reaction mixture suitable for use in the diagnosis of Covid-19 by isothermal amplification method.

IMMUNOASSAY FOR SARS-CoV-2 ANTIBODIES

Resumen de: US20260049994A1

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. Antibodies produced from an immune response against SARS-CoV-2 infection are used to analyze prior exposure to the virus. The present invention provides methods for detecting antibodies in response to SARS-CoV-2 infection in a single multiplex immunoassay.

Therapy, treatment, and process for photodynamic inactivation of COVID-19

Resumen de: US12551717B1

A therapy, treatment and process for inactivating and/or killing COVID-19 (Corona Virus Disease 2019) is provided, including a low-dose, full body, Ultraviolet A1 (UV-A1, 360-400 nm) photon therapy, wherein the UV-A1 photon therapy activates singlet oxygen (1O2), which inactivates and/or kills COVID-19. UV-A1 therapy of the present invention can also be used to help alleviate symptoms and secondary illnesses caused by COVID-19. UV-A1 therapy of the present invention can also be used to help alleviate and treat pre-existing conditions of people that are also suffering from COVID-19 and worsened by COVID-19.

METHOD FOR MANUFACTURING INACTIVATED SARS-COV-2 VACCINE, INACTIVATED SARS-COV-2 VACCINE, METHOD FOR PURIFYING SARS-COV-2 OR INACTIVATED SARS-COV-2, AND SARS-COV-2 ANTIGEN COMPOSITION OR INACTIVATED SARS-COV-2 ANTIGEN COMPOSITION

Resumen de: US20260041762A1

The present invention relates to a production method of an inactivated SARS-CoV-2 vaccine, the method including: a step of bringing a SARS-CoV-2 containing solution or an inactivated SARS-CoV-2 containing solution into contact with a cellulose sulfate ester gel at a pH of 8 or more and 10 or less to adsorb the SARS-CoV-2 or the inactivated SARS-CoV-2 to the gel; then removing impurities; and then eluting and recovering the SARS-CoV-2 or the inactivated SARS-CoV-2.

SUBSTITUTED BENZIMIDAZOLES FOR TREATING VIRAL DISEASES

Resumen de: US20260042743A1

The invention relates to benzimidazole compounds, pharmaceutically acceptable salts thereof and its pharmaceutical compositions for reducing/treating viral infections. The present invention also relates to synthesis of such benzimidazole compounds. The present invention further relates to compositions which comprise such benzimidazole compounds or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination. The compounds of the invention are useful in reducing/treating viral infections particularly coronavirus infections caused by SARS-CoV, MERS-CoV and SARS-CoV-2.

FUSION PROTEIN AND VACCINE

Resumen de: US20260041751A1

The present invention provides a fusion protein which is useful as a vaccine antigen against infectious diseases. A fusion protein including (a) a combination of hemagglutinin and an N-terminal domain of SARS-COV-2, (b) a combination of PspA and a receptor binding domain of SARS-COV-2, (c) a combination of hemagglutinin and respiratory syncytial virus G protein, or (d) a combination of PspA and hemagglutinin, is useful as a vaccine antigen against infectious diseases.

COVID19 mRNA Vaccine

Resumen de: US20260041759A1

A solution has been discovered that provides a more effective Coronavirus vaccine. The solution is an mRNA vaccine encoding a SARS-CoV-2 nucleoprotein (N) (mRNA-N) in combination with an mRNA vaccine encoding SARS-CoV-2 spike protein(S) (mRNA-S). Chemically modified mRNA-N (pseudouridine) and/or chemically modified mRNA-S (pseudouridine) can be synthesized and packaged in lipid nanoparticles (LNP). In mouse and hamster models, it was shown that mRNA-N alone is immunogenic and can significantly diminish viral loads in the mouse lung after prime-boost intramuscular immunization. In addition, the combinatorial mRNA-N/mRNA-S vaccination induces substantially stronger protection against SARS-CoV-2 than vaccination with mRNA-S alone.

Compositions And Methods for Treating Acute Respiratory Distress Syndrome (ARDS) And Inflammatory Disorders Caused by Corona Viruses and Other Respiratory Pathogens or Agents That Mediate Pulmonary Injury, Inflammation or Acute Respiratory Distress, And Related Compositions and Methods for Treating and Preventing Human SARS Coronavirus Infection, COVID-19 Disease and Related Symptoms

Resumen de: US20260041660A1

Methods and compositions containing a phorbol ester or derivative of a phorbol ester are provided for prevention and treatment of sudden acute respiratory syndrome (SARS) coronavirus infection, including SARS-COV-2 infection and related COVID-19 disease. Also provided are methods and compositions for preventing and treating acute inflammatory conditions and related pathogenic injuries, including Acute Respiratory Distress Syndrome (ARDS) and cytokine storm syndrome (CSS) seen in severe SARS-COV-2/COVID-19 cases.

IMMUNE PROPHYLAXIS, THERAPY AND VACCINE FOR COVID-19 AND ITS EMERGING VARIANTS

Resumen de: US20260041760A1

Prophylaxis, immune therapy and vaccine strategies for Covid-19 variants and comorbid conditions such as aging, diabetes, cancer, tuberculosis or HIV. In one mode of invention, the role of the C3 Amplification loop is defined and how it derails the SNS functions or immune function at fluid and tissue levels. The plasticity in subverting C3 amplification control mechanism contribute to survival strategies of SARS-CoV-2 that contributes to various variants that can be reactivated at any stage of life based on immune system of patient that may get compromised with comorbid diseases such as aging, diabetes, cancer and HIV. Therapeutic modulation takes into consideration plasticity of different patient needs and their comorbid conditions by developing varying formulation methods and its combination approaches.

PHARMACEUTICAL COMPOSITION FOR RESISTING INFECTION WITH SARS-COV-2 OR MUTANT THEREOF, AND COMBINED DRUG THEREOF

Resumen de: US20260041761A1

Provided are a pharmaceutical composition for resisting infection with SARS-COV-2 or a mutant thereof, and a combined drug thereof. To solve the problem of the lack of effective prevention and treatment drugs for infection with SARS-COV-2 or a mutant virus thereof, provided are a recombinant protein vaccine and/or an adenovirus vaccine for preventing and/or treating an infection with SARS-COV-2 or a mutant thereof, and in particular, provided are a nasal spray administration compound formulation containing active ingredients of two vaccines, i.e., a recombinant protein vaccine and an adenovirus vaccine, and a combination of the two vaccines for nasal spray administration, which can induce generation of strong antibody and cellular immune responses in vivo and block the binding of a protein S of SARS-COV-2 to an ACE2 receptor of a host cell, thus enabling a host to resist coronavirus infection. Particularly, the present invention has good prevention and treatment effects on various mutant viruses.

PREPARATION METHOD FOR SALT OF CYCLIC CARBONATE NUCLEOSIDE COMPOUND AND CRYSTAL FORM THEREOF

Resumen de: WO2026031273A1

The present invention relates to the technical field of medicine and relates to a salt of a cyclic carbonate nucleoside compound and a crystal thereof, and a preparation method therefor and a use thereof. The salt of the cyclic carbonate nucleoside compound has a structure represented by formula I. When Y is hydrobromic acid and n=1, the salt of the nucleoside compound exists in crystal form A or crystal form B. Crystal form A has the advantages of good physical and chemical stability, good solid-state properties, good water solubility, low hygroscopicity, high oral bioavailability, etc., and can be used in the preparation of a drug for treating and/or alleviating related diseases caused by viruses (especially novel coronavirus, feline infectious peritonitis virus, respiratory syncytial virus, porcine epidemic diarrhea virus, feline calicivirus, etc.).

PARTIAL PEPTIDE OF SARS-COV-2 SPIKE PROTEIN FOR INDUCING FOLLICULAR HELPER T CELLS

Resumen de: EP4692109A1

It aims to provide a composition for inducing follicular helper T cell reactive to SARS-CoV-2. A partial peptide of the spike protein of SARS-CoV-2 is provided, which contains an amino acid sequence selected from the group consisting of the following (1) to (17) and has a full length of 15 or less amino acids:(1) FKIYSKHTPIN (SEQ ID NO: 1),(2) FQFCNDPFLGVYYHK (SEQ ID NO: 2),(3) KRFDNPVLPFN (SEQ ID NO: 3),(4) LLQYGSFCTQL (SEQ ID NO: 4),(5) PPAYTNSFTRGVYYP (SEQ ID NO: 5),(6) CSNLLLQYGSFCTQL (SEQ ID NO: 6),(7) SKRSFIEDLLFNKVT (SEQ ID NO: 7),(8) TGVLTESNKKFLPFQ (SEQ ID NO: 8),(9) TNGTKRFDNPVLPFN (SEQ ID NO: 9),(10) NQFNSAIGKIQ (SEQ ID NO: 10),(11) NFTISVTTEIL (SEQ ID NO: 11),(12) STEIYQAGSTPCNGV (SEQ ID NO: 12),(13) KVFRSSVLHST (SEQ ID NO: 13),(14) EIRASANLAAT (SEQ ID NO: 14),(15) NFTISVTTEILPVSM (SEQ ID NO: 15),(16) FIKQYGDCLGDIAAR (SEQ ID NO: 16), and(17) FIEDLLFNKVTLADA (SEQ ID NO: 17).

SARS-COV-2 VACCINE

Resumen de: WO2026030724A1

Provided herein are recombinant SARS-CoV-2 Spike proteins and fragments thereof comprising the receptor binding domain (RBD), which have utility, for example, for elicitation of an immune response to SARS-CoV-2 in a subject. Also provided are nucleic acid molecules and vectors encoding these proteins, as well as methods of their use and production. In several implementations, the disclosed recombinant SARS-CoV-2 Spike proteins and fragments thereof comprising the RBD, can be used to generate an immune response to SARS-CoV-2 in a subject, for example to treat or prevent or reduce the severity of SARS-CoV-2 infection.

HUMAN BROADLY NEUTRALIZING ANTIBODIES AGAINST BETACORONAVIRUSES

Resumen de: US20260035438A1

The invention provides novel broadly neutralizing antibodies and related antibody compositions against betacoronaviruses, e.g., SARS-CoV-2. Also provided in the invention are polynucleotides and vectors encoding such antibodies, as well as pharmaceutical compositions containing the antibodies or polynucleotides. Therapeutic uses of the antibodies or pharmaceutical compositions in preventing or treating betacoronaviral infections (e.g., SARS-CoV-2 infection) are also encompassed by the invention.

Anti-Sars-COV-2 Antibodies and Uses Thereof

Resumen de: US20260035439A1

Provided herein are monoclonal antibodies that specifically bind to an anti-SARS-CoV-2 spike(S) protein, and methods of using said antibodies.

CORONAVIRUS VACCINE, PRODUCTION AND APPLICATION

Resumen de: US20260034209A1

An SARS-COV-2 recombinant Spike protein is provided. The research process of the protein is as follows: the dominant strain in circulation was identified by screening clinical samples of SARS-COV-2 patients and its mutations in Turkey were evaluated by sequencing the Spike gene. Sequencing data and in silico methods were used to design the Spike antigen and then the novel Spike antigen was docked with the human ACE2 (Angiotensin Converting Enzyme-2) receptor to determine the binding energy. After DNA vaccine construction, HEK293T cells were transfected and analyzed for protein expression capacity by IFA, Western blot and RT-qPCR, then BALB/c mice and K18-hACE2 transgenic mice were immunized with DNA vaccine administered intramuscularly (IM) and intradermally (ID) using an electroporator device three times on days 0, 14 and 56. Humoral and cellular immune responses were then analyzed using recombinant ELISA, Western blot, surrogate virus neutralization assay, microneutralization assay, Cytokine ELISA and flow cytometry.

HUMAN ANTI-SARS-COV-2 SPIKE (S) ANTIBODIES

Resumen de: WO2026030604A1

The present invention includes a monoclonal antibody or antigen-binding fragment thereof, methods of using, detection, recombinant vectors, host cells, kits, variants, and pharmaceutical compositions that include the antibody or antigen-binding fragment thereof that binds to the SARS-CoV-2 Spike protein.

SARS-COV-2 RNA VACCINES AND USES THEREOF

Resumen de: AU2024308310A1

The present disclosure relates to SARS-CoV-2 RNA vaccines and uses thereof. The present disclosure also relates to conventional mRNA vaccines and self-replicating RNA vaccines for the treatment of a SARS-CoV-2 infection or COVID-19.

VIRUS-LIKE VESICLES (VLVS) BASED VACCINES AND METHODS OF PREVENTING, AMELIORATING, AND/OR TREATING COVID-19 AND/OR HEPATOCELLULAR CARCINOMA (HCC)

Resumen de: US20260034208A1

The present disclosure relates to the discovery of compositions and methods for therapeutic immunization for SARS-CoV-2 infections and/or disease(s) associated with expression of Glypican-3 (GPC3), including but not limited to cancers such as hepatocellular carcinoma (HCC). Methods of the disclosure include a method of generating virus like vesicles (VLVs), VLVs comprising SARS-CoV-2 antigens from a high titer VLV producing vector, VLVs comprising GPC3 antigens from a high titer VLV producing vector, methods of treating, ameliorating, and/or preventing SARS-COV-2 infection, methods of inducing a memory T and B cell immune response against SARS-CoV-2 infection in a, methods of treating, ameliorating, and/or preventing GPC3 associated disease, and methods of inducing a memory T and B cell immune response against GPC3 in a subject. Furthermore, the disclosure encompasses a pharmaceutical composition for vaccinating a subject to protect the subject against infection with

HUMAN ANTIBODY AGAINST CORONAVIRUS MUTANT STRAIN, OR ANTIGEN-BINDING FRAGMENT THEREOF

Resumen de: WO2026029035A1

The purpose of the present invention is to provide an antibody against a coronavirus (SARS-CoV-2) mutant strain, in particular, an omicron substrain. Moreover, another purpose of the present invention is to provide a pharmaceutical composition against coronavirus infections, the pharmaceutical composition using said antibody. The present invention provides: an antibody that binds to a spike protein of coronavirus and has the ability to neutralize coronavirus including an omicron substrain, or an antigen-binding fragment thereof; and a pharmaceutical composition for preventing or treating coronavirus infections, the pharmaceutical composition comprising said antibody or antigen-binding fragment thereof.

COMPOSITIONS CONTAINING VERTEPORFIN, RIBAVIRIN, GEMCITABINE, OR COMBINATIONS THEREOF AND METHODS OF USE FOR TREATING COVID-19, CANCER, OR NON CANCER DISEASES

Resumen de: US20260034097A1

Disclosed are pharmaceutical formulations and methods using Verteporfin, Ribavirin, and/or Gemcitabine for use in the treatment of diseases by various routes of administration including inhalation, intratumoral, topical and/or systemic injection administration. This invention relates more specifically to the use of Verteporfin, Ribavirin, Gemcitabine, and/or combinations thereof as an inhaled dry powder treatment for COVID-19 and/or other lung infections, cancer and other non-cancer applications, which may be followed by other treatment regimens including radiation therapy, photodynamic therapy, and/or sonodynamic therapy. These pharmaceutical compositions containing one or more of Verteporfin, Ribavirin, and Gemcitabine may be included in pharmaceutical kits containing the compositions, and to methods for the treatment of cancer and non-cancer diseases with the active agents of the pharmaceutical compositions. The administering of Verteporfin alone or in combination with Ribavirin and Gemcitabine may be followed or co-administered with photodynamic and/or sonodynamic therapy (PDT/SDT).

MACROCYCLIC PEPTIDOMIMETICS AS ANTIVIRAL AGENTS

Resumen de: EP4686470A1

The present invention refers to macrocyclic peptides as covalent reversible inhibitors of SARS-CoV-2 M^pro with a potential broad-spectrum activity against CoV proteases. The compounds are therefore indicated for treating M^pro associated or mediated diseases and conditions, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV2).

-2 MULTI-EPITOPE BASED SARS-COV-2 VACCINE COMPOSITION

Resumen de: WO2026023869A1

The present application relates to a vaccine composition comprising peptides isolated from structural proteins of SARS-CoV-2.

VIRUS-LIKE PARTICLES FOR THE TREATMENT OF SARS-COV2

Resumen de: MX2025014589A

The present disclosure relates to a virus-like particle (VLP) comprising one or more antigens for use as a vaccine. The present disclosure further relates to uses of the vaccine for the treatment of a SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19).

CORONAVIRUS AND INFLUENZA COMPOSITIONS AND METHODS FOR USING THEM

Resumen de: MX2025011740A

An immunogenic composition for inducing immune responses against both influenza and coronaviruses includes: (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, wherein the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer. An immunogenic composition for inducing immune response against influenza includes: (a) at least three hemagglutinin (HA) glycoproteins, wherein each HA glycoprotein is from a different influenza strain, wherein from 30 to 60 µg of HA per strain is present in the composition; and (b) a pharmaceutically acceptable buffer. The immunogenic compositions may include an adjuvant. Methods of stimulating an immune response against SARS-CoV-2, a heterogeneous SARS-CoV-2 strain, an influenza virus, or a combination thereof include the administration of the immunogenic compositions.

-2 METHOD FOR EXTRACTING EPITOPES EFFECTIVE IN PREVENTING OR TREATING SARS-COV-2

Resumen de: WO2026023870A1

The present application relates to a method for extracting epitopes effective in the prevention or treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the method comprising the steps of: (a) extracting, from an anti-spike antibody database, first structural data including known structures and second structural data including unknown structures, and extracting, from a SARS-CoV-2 proteome database, third structural data including known structures; (b) carrying out 3D modeling on the second structural data, and classifying the third structural data into a first group including structural proteins and a second group including both structural proteins and non-structural proteins; (c) carrying out spike-antibody docking on the basis of the first group and the second structural data on which 3D modeling has been carried out; (d) constructing a spike-antibody database on the basis of the first structural data and the docked data, and predicting conformational epitopes on the basis of the second group; (e) characterizing epitopes on the basis of the spike-antibody database and the conformational epitopes; and (f) selecting final epitopes on the basis of analysis results.

ANTIGENO RECOMBINANTE DE LA PROTEINA SPIKE DEL SARS-COV -2.

Nº publicación: MX2024009232A 03/02/2026

Solicitante:

INSTITUTO POLITECNICO NAC [MX]
INSTITUTO POLIT\u00C9CNICO NACIONAL